As filed with the Securities and Exchange Commission on August 9, 2018
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
LOXO ONCOLOGY, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware |
|
46-2996673 |
(State or Other Jurisdiction |
|
(I.R.S. Employer |
Loxo Oncology, Inc.
281 Tresser Boulevard, 9th Floor
Stamford, CT 06901
(Address of Principal Executive Offices) (Zip Code)
2014 Equity Incentive Plan
Non-Plan Stock Option Agreements (Inducement Stock Option Awards)
(Full Title of the Plan)
Joshua H. Bilenker, M.D.
President and Chief Executive Officer
Loxo Oncology, Inc.
281 Tresser Boulevard, 9th Floor
Stamford, CT 06901
(Name and Address of Agent for Service)
(203) 653-3880
(Telephone Number, including area code, of agent for service)
Copies to:
Robert A. Freedman, Esq.
Fenwick & West LLP
Silicon Valley Center
801 California Street
Mountain View, California 94041
(650) 988-8500
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of large accelerated filer, accelerated filer, and smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer x |
|
Accelerated filer o |
|
|
|
Non-accelerated filer o |
|
Smaller reporting company o |
|
|
|
|
|
Emerging growth company o |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
| |||
Title of Securities |
|
Amount To Be |
|
Proposed Maximum |
|
Proposed Maximum |
|
Amount of |
| |||
Common Stock, $0.0001 par value per share |
|
|
|
|
|
|
|
|
| |||
To be issued under the 2014 Equity Incentive Plan, as amended |
|
1,500,000 |
(1) |
$ |
167.75 |
|
$ |
251,625,000.00 |
|
$ |
31,327.32 |
|
Non-Plan Stock Option Agreements (Inducement Stock Option Awards) |
|
98,525 |
(2) |
$ |
167.75 |
|
$ |
16,527,568.75 |
|
$ |
2,057.69 |
|
Total |
|
1,598,525 |
|
N/A |
|
$ |
268,152,568.75 |
|
$ |
33,385.01 |
|
(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), this Registration Statement shall also cover any additional shares of the Registrants Common Stock that become issuable under the Registrants 2014 Equity Incentive Plan, as amended (the 2014 EIP) in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrants receipt of consideration that increases the number of the outstanding shares of the Registrants Common Stock.
(2) Represents shares of the Registrants common stock issuable pursuant to Non-Plan Stock Option Agreements (Inducement Stock Option Awards) to employees.
(3) Estimated in accordance with Rules 457(c) and 457(h) under the Securities Act solely for the purpose of calculating the registration fee. The proposed maximum offering price per share was computed by averaging the high and low prices of a share of Registrants Common Stock as reported on The Nasdaq Global Select Market on August 3, 2018.
(4) Calculated in accordance with Rules 457(c) and 457(h) under the Securities Act solely for the purpose of computing the registration fee on the basis of the average of the high and low prices of the Registrants Common Stock as reported on The Nasdaq Global Select Market on August 3, 2018.
STATEMENT PURSUANT TO GENERAL INSTRUCTION E TO FORM S-8
REGISTRATION OF ADDITIONAL SECURITIES
This registration statement (the Registration Statement) hereby incorporates by reference the contents of the earlier registration statements on Form S-8 (registration numbers 333-197800, 333-203081, 333-210214, 333-216503 and 333-223359) filed by Loxo Oncology, Inc.
PART II
Information Required in the Registration Statement
Item 8. Exhibits.
Exhibit |
|
|
|
Incorporated by Reference |
|
Filed | ||||||
Number |
|
Exhibit Description |
|
Form |
|
File No. |
|
Exhibit |
|
Filing Date |
|
Herewith |
|
|
|
|
|
|
|
|
|
|
|
|
|
5.1 |
|
|
|
|
|
|
|
|
|
|
X | |
|
|
|
|
|
|
|
|
|
|
|
|
|
23.1 |
|
Consent of Ernst & Young LLP, independent registered public accounting firm. |
|
|
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
23.2 |
|
Consent of CohnReznick LLP, independent registered public accounting firm. |
|
|
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
23.3 |
|
|
|
|
|
|
|
|
|
|
X | |
|
|
|
|
|
|
|
|
|
|
|
|
|
24.1 |
|
Power of Attorney (incorporated by reference to Page II-3 of this Registration Statement). |
|
|
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.1 |
|
2014 Equity Incentive Plan, as amended April 23, 2018 and forms of award agreements. |
|
10-Q |
|
001-36562 |
|
10.1 |
|
8/9/18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.2 |
|
Non-Plan Stock Option Agreement (Inducement Stock Option Award). |
|
10-Q |
|
001-36562 |
|
10.2 |
|
8/9/18 |
|
|
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Stamford, State of Connecticut, on this 9th day of August, 2018.
|
Loxo Oncology, Inc. | |
|
| |
|
By: |
/s/ Joshua H. Bilenker, M.D. |
|
|
Joshua H. Bilenker, M.D. |
|
|
President, Chief Executive Officer and Director |
KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned officers and directors of Loxo Oncology, Inc., a Delaware corporation, do hereby constitute and appoint Joshua H. Bilenker, M.D., President, Chief Executive Officer and Director and Jennifer Burstein, Senior Vice President of Finance, the lawful attorneys-in-fact and agents with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents, and any one of them, determine may be necessary or advisable or required to enable said corporation to comply with the Securities Act of 1933, as amended, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with this Registration Statement. Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective, and supplements to this Registration Statement, and to any and all instruments or documents filed as part of or in conjunction with this Registration Statement or amendments or supplements thereof, and each of the undersigned hereby ratifies and confirms that all said attorneys and agents, or any one of them, shall do or cause to be done by virtue hereof.
IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Joshua H. Bilenker, M.D. |
|
President, Chief Executive Officer and Director (Principal Executive Officer) |
|
August 9, 2018 |
Joshua H. Bilenker, M.D. |
|
|
|
|
|
|
|
|
|
/s/ Jennifer Burstein |
|
Senior Vice President of Finance (Principal Financial Officer and Principal Accounting Officer) |
|
August 9, 2018 |
Jennifer Burstein |
|
|
|
|
|
|
|
|
|
/s/ Steven A. Elms |
|
Director |
|
August 9, 2018 |
Steven A. Elms |
|
|
|
|
|
|
|
|
|
/s/ Keith T. Flaherty, M.D. |
|
Director |
|
August 9, 2018 |
Keith T. Flaherty, M.D. |
|
|
|
|
|
|
|
|
|
/s/ Alan Fuhrman |
|
Director |
|
August 9, 2018 |
Alan Fuhrman |
|
|
|
|
|
|
|
|
|
/s/ Steve D. Harr, M.D. |
|
Director |
|
August 9, 2018 |
Steve Harr, M.D. |
|
|
|
|
|
|
|
|
|
/s/ Lori Kunkel, M.D. |
|
Director |
|
August 9, 2018 |
Lori Kunkel, M.D. |
|
|
|
|
|
|
|
|
|
/s/ Timothy Mayleben |
|
Director |
|
August 9, 2018 |
Timothy Mayleben |
|
|
|
|
|
|
|
|
|
/s/ Avi Z. Naider |
|
Director |
|
August 9, 2018 |
Avi Z. Naider |
|
|
|
|